The study is designed to determine whether a currently licensed version of botulinum toxin
(Dysport®) is effective for the treatment of pain that has developed and/or persisted for
months or years around the scar of a previous surgical site, and whether this condition could
be suitable for the testing of similar new medicines. The study will compare three different
doses of Dysport® to see if there is benefit and/or a best dose for treating persistent
post-surgery scar pain.
Phase:
Phase 2
Details
Lead Sponsor:
Ipsen
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A Lidocaine onabotulinumtoxinA Pharmaceutical Solutions